College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia.
College of Health and Medicine, Flinders University, Bedford Park, South Australia, Australia
BMJ Open. 2022 May 2;12(5):e050681. doi: 10.1136/bmjopen-2021-050681.
Understanding the prevalence of cannabis use among tobacco smokers has important implications for research in terms of intervention effectiveness and measurement in smoking cessation trials. The co-use of these substances also has important implications for health service planning, specifically ensuring appropriate and adequate clinical treatment. To date, there have been no synthesis of the literature on the prevalence of tobacco and cannabis co-use in adult clinical populations. Improved understanding of the current prevalence, route of administration and specific subpopulations with the highest rates of tobacco and cannabis co-use will support future intervention development. We aim to provide a pooled estimate of the percentage of smokers who report using cannabis and to examine the prevalence of co-use by sociodemographic characteristics.
We will conduct a systematic review using six scientific databases with published articles from 2000 to 2022 inclusive (CENTRAL, CINAHL, EMBASE, Medline, PsycINFO, Psychology and Behavioural Sciences Collection, Scopus). Peer-reviewed journal articles published in English that report on tobacco and cannabis use will be included. Rates of co-use (simultaneous or sequentially) and routes of administration will be assessed. Use in populations groups will be described. Quality assessments will be conducted for all included studies. Data will be synthesised using a narrative approach. This study will be conducted from June 2022 to the end of August 2022.
This review is based on previously published data and, therefore, ethical approval or written informed consent will not be required. It is the intention of the research team to disseminate the results of the systematic review as a peer-reviewed publication and conference presentations.
CRD42020194051.
了解吸烟者中使用大麻的流行情况，对于干预效果研究和戒烟试验中的测量具有重要意义。这些物质的共同使用也对卫生服务规划具有重要意义，特别是要确保提供适当和充分的临床治疗。迄今为止，尚无成人临床人群中烟草和大麻共同使用的文献综述综合。更好地了解当前的流行率、给药途径以及烟草和大麻共同使用率最高的特定亚人群，将有助于未来干预措施的发展。我们旨在提供一个报告吸烟人群中使用大麻的百分比的综合估计，并按社会人口统计学特征检查共同使用的流行率。
我们将使用六个科学数据库进行系统综述，这些数据库包含 2000 年至 2022 年期间发表的文章（CENTRAL、CINAHL、EMBASE、Medline、PsycINFO、Psychology and Behavioural Sciences Collection、Scopus）。将纳入报告烟草和大麻使用情况的同行评审期刊文章。将评估共同使用（同时或先后）的比率和给药途径。将描述在人群中的使用情况。将对所有纳入的研究进行质量评估。将使用叙述方法对数据进行综合。本研究将于 2022 年 6 月至 2022 年 8 月底进行。
本综述基于先前发表的数据，因此不需要伦理批准或书面知情同意。研究团队打算将系统评价的结果作为同行评审出版物和会议演讲进行传播。
PROSPERO 注册号：CRD42020194051。
